A study comparing two medicines used in treating excessive bleeding and pain abdomen in women

Comparison Of Efficacy Of Letrozole And Ormeloxifene In The Management of Abnormal Uterine Bleeding(AUB-A)- A Randomised Controlled Study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103054

Enrollment

128

Registered

2026-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N800- Endometriosis of uterus

Interventions

Intervention1: Letrozole: Letrozole 2.5mg thrice weekly for 24 weeks Control Intervention1: Ormeloxifene: Ormeloxifene 60mg twice weekly for 12 weeks followed by 60mg weekly for next 12 weeks

Eligibility

Inclusion criteria

Inclusion criteria: women aged more than 18 years who are diagnosed with adenomyosis based on MUSA criteria

Exclusion criteria

Exclusion criteria: Other asoociated pelvic pathology, contraindications to ormeloxifene/letrozole,women with severe anemia requiring transfusions

Design outcomes

Primary

Measure	Time frame
efficacy of letrozole with ormeloxifene in reducing the symptoms and improving hemoglobin among women with abnormal uterine bleeding due to adenomyosisTimepoint: 3 months, 6 months	—

Secondary

Measure	Time frame
efficacy of letrozole with ormeloxifne in improving overall quality of life among women with abnormal uterine bleeding due to adenomyosisTimepoint: 3 months, 6 months	—

Countries

India

Contacts

Public Contactveluri lakshmi vennela reddy

JIPMER

ns.drkubera@gmail.com9442550604

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026